A new therapeutic class of oral agents firstly used for the treatment of type 2 diabetes mellitus is represented by gliflozines or sodium-glucose co-transporter 2 (SGLT2) inhibitors. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.